|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0026336,
umls-concept:C0026809,
umls-concept:C0144576,
umls-concept:C0205195,
umls-concept:C0205221,
umls-concept:C0302350,
umls-concept:C0332161,
umls-concept:C0346647,
umls-concept:C0442034,
umls-concept:C0521447,
umls-concept:C1274040,
umls-concept:C1521761,
umls-concept:C1879547,
umls-concept:C1999216
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-4-12
|
|
pubmed:abstractText |
Paclitaxel (PTX) is a useful treatment for peritoneal dissemination of malignant tumors. However, chemoresistance due to PTX-induced nuclear factor ?B (NF-?B) activation is an important cause of suboptimal therapeutic effect. We previously reported nafamostat mesilate (FUT175) inhibits NF-?B activation and promotes apoptosis in pancreatic cancer. We hypothesized that addition of FUT175 to PTX may enhance the antitumor effect in peritoneal dissemination of pancreatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1536-4828
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
600-7
|
|
pubmed:meshHeading |
pubmed-meshheading:21343836-Animals,
pubmed-meshheading:21343836-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:21343836-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:21343836-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21343836-Apoptosis,
pubmed-meshheading:21343836-Blotting, Western,
pubmed-meshheading:21343836-Caspase 8,
pubmed-meshheading:21343836-Cell Line, Tumor,
pubmed-meshheading:21343836-Cell Nucleus,
pubmed-meshheading:21343836-Cell Proliferation,
pubmed-meshheading:21343836-Cell Survival,
pubmed-meshheading:21343836-Drug Synergism,
pubmed-meshheading:21343836-Guanidines,
pubmed-meshheading:21343836-Humans,
pubmed-meshheading:21343836-Male,
pubmed-meshheading:21343836-Mice,
pubmed-meshheading:21343836-Mice, Inbred BALB C,
pubmed-meshheading:21343836-Mice, Nude,
pubmed-meshheading:21343836-NF-kappa B,
pubmed-meshheading:21343836-Paclitaxel,
pubmed-meshheading:21343836-Pancreatic Neoplasms,
pubmed-meshheading:21343836-Peritoneum,
pubmed-meshheading:21343836-Phosphorylation,
pubmed-meshheading:21343836-Treatment Outcome,
pubmed-meshheading:21343836-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Combination paclitaxel and inhibitor of nuclear factor ?B activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer.
|
|
pubmed:affiliation |
Department of Surgery, Institute of DNA Medicine, Jikei University School of Medicine, Minato-ku, Tokyo, Japan. sheetan@jikei.ac.jp
|
|
pubmed:publicationType |
Journal Article
|
